Analyst Alerts: Facebook, Vertex May 29th
Facebook (NASDAQ:FB): Wedbush said it continues to expect Facebook to post significant long-term revenue growth despite short-term issues stemming from the NASDAQ IPO glitches, the oversupply of shares, and reports of material information being selectively disclosed to analysts. The firm maintains an Outperform rating on Facebook shares with a $44 price target.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): Morgan Stanley lowered Vertex’s price target to $46 due to the worse than expected CF data. Shares are Equal Weight rated.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.